PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer
Ticker: PYPD · Form: 6-K · Filed: Aug 12, 2025 · CIK: 1611842
| Field | Detail |
|---|---|
| Company | Polypid Ltd. (PYPD) |
| Form Type | 6-K |
| Filed Date | Aug 12, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, personnel, biotech
TL;DR
PolyPid names new CMO, Dr. Nurit Tweezer-Zaks, effective Aug 12, 2025.
AI Summary
PolyPid Ltd. announced on August 12, 2025, the appointment of Dr. Nurit Tweezer-Zaks as its new Chief Medical Officer. Dr. Tweezer-Zaks brings extensive experience in clinical development and medical affairs to the role. This appointment is effective immediately and is expected to bolster the company's leadership team as it advances its pipeline.
Why It Matters
The appointment of a new Chief Medical Officer is crucial for a biotechnology company like PolyPid, as this role is central to guiding clinical strategy and execution, directly impacting the progression of drug candidates.
Risk Assessment
Risk Level: low — This filing is an announcement of a key executive appointment, which is a routine corporate event and does not inherently carry significant financial risk.
Key Players & Entities
- PolyPid Ltd. (company) — The company making the announcement.
- Dr. Nurit Tweezer-Zaks (person) — Newly appointed Chief Medical Officer.
- August 12, 2025 (date) — Date of the press release and appointment.
FAQ
Who has been appointed as the new Chief Medical Officer of PolyPid Ltd.?
Dr. Nurit Tweezer-Zaks has been appointed as the new Chief Medical Officer of PolyPid Ltd.
When was the press release announcing this appointment issued?
The press release was issued on August 12, 2025.
What is the primary role of the Chief Medical Officer at PolyPid Ltd.?
The Chief Medical Officer is responsible for clinical development and medical affairs, guiding the company's clinical strategy.
Is this appointment effective immediately?
Yes, the appointment of Dr. Nurit Tweezer-Zaks is effective immediately.
Which SEC forms are mentioned in relation to PolyPid's registration statements?
The filing mentions PolyPid's registration statements on Form F-3, specifically File No. 333-276826, File No. 333-280658, and File No.
Filing Stats: 296 words · 1 min read · ~1 pages · Grade level 9 · Accepted 2025-08-12 08:05:02
Filing Documents
- ea0252624-6k_polypid.htm (6-K) — 13KB
- ea025262401ex99-1_polypid.htm (EX-99.1) — 13KB
- ex99-1_001.jpg (GRAPHIC) — 2KB
- 0001213900-25-074642.txt ( ) — 30KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. POLYPID LTD. Date: August 12, 2025 By: /s/ Dikla Czaczkes Akselbrad Name : Dikla Czaczkes Akselbrad Title: Chief Executive Officer 3